On January 15, Singapore’s Health Sciences Authority (HSA) and Indonesia’s Food and Drug Authority (BPOM) signed a Memorandum of Understanding (MoU), marking a significant milestone in cross-border cooperation on health products. The MoU enables both agencies to share regulatory information related to medicines and complementary health products, strengthening public health protection through enhanced safety monitoring and quality assurance across Singapore and Indonesia. The agreement also supports joint assessments, improved clinical-trial oversight, capacity-building initiatives, and collaborative projects, including the application of artificial intelligence in health product regulation.
As the only two countries in Southeast Asia to have achieved WHO Listed Authority status, granted to national regulators that meet the highest international standards for the oversight of medical products, the partnership is also expected to generate positive commercial spillovers. HSA Chief Executive Officer Adjunct Professor Dr. Raymond Chua noted that the MoU could benefit businesses operating in both markets by establishing stronger, more predictable regulatory frameworks and facilitating innovation in the life sciences sector.
